Septerna, Inc. (NASDAQ:SEPN) Stock Has Average Price Target of $52.44 According to Analysts

Septerna, Inc. (NASDAQ:SEPN) has received an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $52.44.

Several equities research analysts recently commented on SEPN shares. Stifel Nicolaus set a $49.00 target price on Septerna in a report on Tuesday, August 11th. Guggenheim upped their target price on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. JPMorgan Chase & Co. increased their price target on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th.

Insider Buying and Selling at Septerna

In other news, COO Elizabeth Bhatt sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the sale, the chief operating officer owned 174,209 shares in the company, valued at $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,647,265.96. This represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 31,667 shares of company stock valued at $1,341,010. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new stake in Septerna during the fourth quarter worth approximately $88,000. The Manufacturers Life Insurance Company acquired a new position in Septerna in the second quarter worth approximately $211,000. Canada Pension Plan Investment Board acquired a new position in Septerna in the second quarter worth approximately $298,000. Legal & General Group Plc bought a new position in shares of Septerna in the second quarter valued at $337,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Septerna in the fourth quarter valued at $319,000.

Septerna Trading Down 3.0%

SEPN stock opened at $36.42 on Friday. Septerna has a 52 week low of $17.55 and a 52 week high of $51.10. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -67.44 and a beta of 2.29. The firm’s 50-day moving average is $39.44 and its two-hundred day moving average is $33.30.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, equities research analysts predict that Septerna will post -1.41 earnings per share for the current year.

Septerna Company Profile

Septerna, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address.